NOUS-209 is under clinical development by Nouscom and currently in Phase II for Gastric Cancer. According to GlobalData, Phase II drugs for Gastric Cancer have a 30% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how NOUS-209’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
NOUS-209 overview
NOUS-209 is under development for the treatment of solid tumors incuding gastric cancer, colorectal cancer and gastroesophageal junction microsatellite instable cancers. The therapeutic candidate is developed based on Exovax platform which comprises of human great apes adenovirus (GAd) and modified vaccinia virus ankara (MVA) viral vectors encoding cancer neoantigens and AGE1.CR.pIX platform. It is administered through intramuscular route.
Nouscom overview
Nouscom is a immunotherapy company. It develops a genetic neoantigen vaccine and oncolytic viruses for prevention and treatment of cancer. Nouscom is headquartered in Basel, Switzerland.
For a complete picture of NOUS-209’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
